Psyence Biomedical Ltd Stock Today
| PBM Stock | USD 7.91 -1.12 -12.40% |
Performance
| Odds Of Distress
|
Psyence Biomedical (PBM) is trading at $7.91 as of April 26, 2026, representing 12.4% down in today's trading with an intraday range between $7.87 and $10.14. Psyence Biomedical carries 9% estimated odds of financial distress over the next several years, indicating a relatively small probability of operating stress. Measured over 90 trading days, Psyence Biomedical has produced modest risk-adjusted performance on a risk-adjusted basis. The performance scores apply to the period beginning January 26, 2026 and ending April 26, 2026. Learn more.
IPO Date 25th of January 2024 | Asset Type Stock | Category Healthcare | Classification Health Care |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Stock Highlights
Psyence Biomedical Ltd (PBM) is listed on NASDAQ Exchange in USA. Psyence Biomedical is categorized in the Biotechnology sector. PBM runs in the Biotechnology sector. With a market cap of 18.14 M, Psyence Biomedical Ltd screens as a micro-cap company within biotechnology companies. Other size-related inputs worth noting are about 2.29 M shares outstanding, enterprise value near 18.69 M, and a workforce of about 12 people. PBM has 43.15 K shares sold short (2.19 days to cover). Psyence Biomedical operates as a research-driven pharmaceutical developer where revenue is driven by drug pipeline progression, regulatory approvals, and patent-protected sales. Psyence Biomedical Ltd has about 281.63 K in cash as of latest reporting with -3.73 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. Psyence Biomedical financial stability analysis Ownership Allocation Psyence Biomedical holds a 4.44% of its outstanding shares held by insiders and 1.43% owned by institutional investors. Check Psyence Ownership DetailsPsyence Biomedical Attention vs Price Pattern
This indicator helps contextualize how headlines and social activity shape market expectations. Behavioral sentiment models show that Psyence Biomedical Ltd currently carries a strongly positive sentiment profile, based on evaluation of 2 recent information signals as of 2026-04-20.
Psyence Biomedical Ltd reported an ESG Environmental Score of 62.33, an ESG Governance Score of 60.16, and an ESG Social Score of 70.50. Compared to Biotechnology peers, Psyence Biomedical reflects moderately elevated ESG metrics. ESG indicators help describe non-financial risk and operational durability. Recent ESG signals may affect risk framing. This summary is informational in nature.
Environmental | Governance | Social |
Stock Notable Updates
| Legal Name | Psyence Biomedical Ltd. Common Shares |
| Co-Founder, Executive Chairman & CEO | Jody Aufrichtig |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare, (View all Sectors) |
Psyence Biomedical Ltd reported a Return On Capital Employed of -60.0%, a Return On Equity of 13.0%, and a Return On Tangible Assets of 17.0%. Reviewing balance sheet structure and operating performance, Psyence Biomedical Ltd appears to maintain pressured financial positioning. Profitability remains under pressure, with return on assets below breakeven in the current period.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 649.3 K | 683.5 K |
|
| |||||
| Total Assets | 6.3 M | 6.6 M |
|
| |||||
| Total Current Assets | 7.9 M | 7.5 M |
|
|
Current Assets
Psyence Biomedical Ltd reported $6.3 million in Total Assets, a Return On Tangible Assets of 17.0%, and a Debt To Assets of 872.0%. The company's key financial metrics picture is further described by $646 thousand in Non Current Assets Total.
Psyence Biomedical Historical Income Statement
Research Development stood at 307,951 as of December 31, 2025. As of last Sunday, EBITDA is up from prior levels to approximately 968.9 K, while Selling General Administrative is about 2.3 M. View More FundamentalsPsyence Biomedical Ltd Against Markets
Stock Overview, Methodology & Data Sources
Psyence Biomedical engages in the exploration of mineral properties in Canada. Psyence Biomedical employs 12 people. Headquarters are in 121 Richmond Street West, Toronto, ON, Canada, M5H2K1. Current valuation profile shows market cap 18.14 M, P/B 1.53, ROE -74.29%. Psyence Biomedical operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Financial reporting is combined with risk and trading context. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for Psyence Biomedical Ltd is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Psyence (USA Stocks:PBM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Psyence Biomedical Ltd may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board
Psyence Biomedical Corporate Management
| Taryn Vos | General Counsel | Profile | |
| Neil MD | Global Head of Clinical Development | Profile | |
| Tony Budden | Chief Officer | Profile | |
| MaryElizabeth Gifford | Executive Impact | Profile |